BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9924431)

  • 1. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.
    Lipponen P; Aaltoma S; Kosma VM; Ala-Opas M; Eskelinen M
    J Pathol; 1998 Oct; 186(2):157-64. PubMed ID: 9924431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma.
    Ross JS; del Rosario AD; Bui HX; Kallakury BV; Okby NT; Figge J
    Mod Pathol; 1996 Aug; 9(8):854-60. PubMed ID: 8871928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma.
    Böhm JP; Niskanen LK; Pirinen RT; Kiraly K; Kellokoski JK; Moisio KI; Eskelinen MJ; Tulla HE; Hollmen S; Alhava EM; Kosma VM
    J Pathol; 2000 Nov; 192(3):321-7. PubMed ID: 11054715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer.
    Kawano T; Nakamura Y; Yanoma S; Kubota A; Furukawa M; Miyagi Y; Tsukuda M
    Auris Nasus Larynx; 2004 Mar; 31(1):35-41. PubMed ID: 15041052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD44s and CD44v6 in diagnosis and prognosis of human bladder cancer.
    Omran OM; Ata HS
    Ultrastruct Pathol; 2012 May; 36(3):145-52. PubMed ID: 22559040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells.
    Kuncová J; Urban M; Mandys V
    APMIS; 2007 Nov; 115(11):1194-205. PubMed ID: 18092951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD44s and CD44v6 expression in localized T1-T2 conventional renal cell carcinomas.
    Daniel L; Lechevallier E; Giorgi R; Lindner V; De Fromont M; Vieillefond A; Coulange C; Figarella-Branger D
    J Pathol; 2001 Mar; 193(3):345-9. PubMed ID: 11241414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of cathepsin D in transitional cell bladder tumours.
    Lipponen PK
    J Pathol; 1996 Jan; 178(1):59-64. PubMed ID: 8778318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study.
    Morris SF; O'Hanlon DM; McLaughlin R; McHale T; Connolly GE; Given HF
    Eur J Surg Oncol; 2001 Sep; 27(6):527-31. PubMed ID: 11520083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression.
    Saegusa M; Machida D; Hashimura M; Okayasu I
    J Pathol; 1999 Nov; 189(3):326-37. PubMed ID: 10547593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma.
    Chai CY; Chen WT; Hung WC; Kang WY; Huang YC; Su YC; Yang CH
    J Clin Pathol; 2008 May; 61(5):658-64. PubMed ID: 17908805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer.
    Müller W; Schneiders A; Heider KH; Meier S; Hommel G; Gabbert HE
    J Pathol; 1997 Oct; 183(2):222-7. PubMed ID: 9390037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma.
    Pirinen R; Hirvikoski P; Böhm J; Kellokoski J; Moisio K; Virén M; Johansson R; Hollmén S; Kosma VM
    Hum Pathol; 2000 Sep; 31(9):1088-95. PubMed ID: 11014576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44 expression in sinonasal melanomas: is loss of isoform expression associated with advanced tumour stage?
    Regauer S; Ott A; Berghold A; Beham A
    J Pathol; 1999 Jan; 187(2):184-90. PubMed ID: 10365093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis.
    Ristamäki R; Joensuu H; Söderström KO; Jalkanen S
    J Pathol; 1995 Jul; 176(3):259-67. PubMed ID: 7545748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
    Nguyen VN; Mirejovský T; Melinová L; Mandys V
    Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis.
    Lipponen PK; Aaltomaa S
    J Pathol; 1994 Aug; 173(4):333-9. PubMed ID: 7965393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma.
    Inagaki H; Banno S; Wakita A; Ueda R; Eimoto T
    Mod Pathol; 1999 May; 12(5):546-52. PubMed ID: 10349995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classic prognostic factors, flow cytometric data, nuclear morphometric variables and mitotic indexes as predictors in transitional cell bladder cancer.
    Lipponen PK; Eskelinen MJ; Kiviranta J; Nordling S
    Anticancer Res; 1991; 11(2):911-6. PubMed ID: 2064350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p53 protein has no independent prognostic value in breast cancer.
    Pietiläinen T; Lipponen P; Aaltomaa S; Eskelinen M; Kosma VM; Syrjänen K
    J Pathol; 1995 Nov; 177(3):225-32. PubMed ID: 8551383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.